三联雾化吸入治疗COPD急性加重期的临床疗效

目的:观察普米克令舒与万托林及爱全乐联合雾化吸入治疗慢性阻塞性肺病(COPD)急性加重期的临床疗效.方法:90例COPD急性加重期住院患者随机分为治疗组和对照组,治疗组给予普米克令舒1mg、万托林0.5ml及爱全乐500ug雾化吸入,2次/日;对照组常规治疗不使用任何糖皮质激素.观察两组患者治疗后呼吸困难评分,肺功能(FEV1%)变化及不良反应情况.结果:治疗3天后,治疗组呼吸困难改善及肺功能提高均明显优于对照组,两组间有显著性的差异.治疗组不良反应很少发生.结论:普米克令舒与万托林及爱全乐联合雾化吸入能明显改善慢性阻塞性肺病患者的呼吸困难症状及肺功能,可作为急性加重期的常规治疗.

Clinical effects of inhaling salbutamol and ipratropium and budesonide for treatment of acute exacerbations of COPD

Objective To observe Clinical effects of salbutamol and ipratropium and budesonide for treatment of acute exacerbations of COPD. Methods 90 patients of acute exacerbations of COPD were randomly divided into treatment group cases who received conventional medical therapy plus budesonide. and control group cases who received conventional medical therapy without glucocorticoids. Levels of dyspnea and pulmonary function were observed before and after treatment. Results Compare to control group cases, treatment group cases had significant improvement in levels of dyspnea and 72 hours of treatment(P<0.05), pulmonary function had been significantly increased after 72 hours of treatment(P<0.05).Conclusion The results suggest that inhaling salbutamol and ipratropium and budesonide can improve levels of dyspnea and pulmonary function.